急性髓系白血病患者可测量残留病灶的二代测序监测
本研究采用双链唯一分子标识符(UMI)为基础的二代测序(NGS)捕获面板,对98例经强化化疗后首次完全缓解的成人急性髓系白血病(AML)患者进行可测量残留病灶(MRD)评估。结果显示,双链UMI-NGS可将伪影调用降低最多20倍,可准确定量至0.01%变异等位基因频率;排除DNMT3A、TET2、ASXL1、IDH1和IDH2突变后,NGS-MRD阳性>0.1%在第二疗程后与较差结局显著相关,且与多参数流式细胞术(MFC-MRD)联合可识别第一疗程后结局特别差的双阳性亚组。
要点
- 双链UMI-NGS将伪影调用较传统测序降低最多20倍,可准确定量至0.01%变异等位基因频率。
- 排除DNMT3A、TET2、ASXL1、IDH1和IDH2突变后,NGS-MRD>0.1%在第二疗程后与较差OS和RFS显著相关。
- MFC-MRD与NGS-MRD双阳性亚组在第一疗程后结局特别差。
核心结论
- 双链UMI-NGS是AML中MRD评估的敏感、定量方法,可提供与MFC-MRD互补的预后信息。
研究设计与样本
- 研究纳入98例经强化化疗后首次完全缓解的成人AML患者,采用双链UMI为基础的NGS捕获面板评估MRD。
主要发现
- 误差减少分析显示,双链UMI-NGS较传统测序伪影调用降低最多20倍。
- 系列稀释的线性研究证实可准确定量至0.01%变异等位基因频率。
- 在该队列中,一个疗程化疗后NGS-MRD阳性对总生存(OS)或无复发生存(RFS)无显著影响。
- 排除DNMT3A、TET2、ASXL1、IDH1和IDH2突变后,NGS-MRD阳性>0.1%在第二疗程后与较差结局显著相关(OS:风险比[HR]=3.04,p=0.0173;RFS:HR=2.83,p=0.0097)。
- 将MFC-MRD与NGS-MRD联合可识别第一疗程后结局特别差的双阳性亚组(OS:HR=7.98,p<0.001;RFS:HR=7.87,p<0.001)。
关键数值与推荐
- NGS-MRD阳性阈值>0.1%,排除DNMT3A、TET2、ASXL1、IDH1和IDH2突变。
- 双链UMI-NGS可准确定量至0.01%变异等位基因频率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) is a strong prognostic factor in acute myeloid leukaemia (AML). Next-generation sequencing (NGS) offers promise but must distinguish true signal from background. We assessed MRD in 98 adult AML patients in first complete remission after intensive chemotherapy using a duplex unique molecular identifier (UMI)-based NGS capture panel. Error reduction analysis showed up to a 20-fold decrease in artefactual calls versus conventional sequencing. Linearity studies with serial dilutions confirmed accurate quantification down to 0.01% variant allele frequency. In this cohort, NGS-MRD positivity did not significantly affect overall survival (OS) or relapse-free survival (RFS) after one course of chemotherapy. However, NGS-MRD positivity >0.1%, excluding DNMT3A, TET2, ASXL1, IDH1 and IDH2 mutations, was significantly associated with inferior outcomes after two courses (OS: hazard ratio [HR] = 3.04, p = 0.0173; RFS: HR = 2.83, p = 0.0097). Combining multiparameter flow cytometry (MFC-MRD) with NGS-MRD identified a double-positive subgroup with particularly poor outcomes after the first course (OS: HR = 7.98, p < 0.001; RFS: HR = 7.87, p < 0.001). These findings underscore that duplex UMI-based NGS is a sensitive, quantitative approach for MRD assessment in AML, offering prognostic information complementary to MFC-MRD.
引用
- Boudry A, Goursaud L, Lebon D, et al. Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia. Br J Haematol. 2025. PMID: 40903763. doi:10.1111/bjh.70135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。